Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O- methyl-sn-glycero-3-phosphocholine

Cancer Research

Volumn 57, Issue 10, 1997, Pages 1915-1921

  Ahmad, Imran ^a   Filep, Julius J ^a   Franklin, J Craig ^a   Janoff, Andrew S ^a   Masters, Gregg R ^a   Pattassery, Judy ^a   Peters, Andrew ^a   Schupsky, James J ^a   Zha, Yan ^a   Mayhew, Eric ^a  

^a Liposome Company Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EDELFOSINE; LIPOSOME;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA P 388; LUNG CANCER; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ASCITIC FLUID; CARCINOMA, LEWIS LUNG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HEMOLYSIS; LEUKEMIA P388; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NECROSIS; PHOSPHOLIPID ETHERS;

EID: 15644378952     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Berdel, W. E., Andreesen, R., and Munder, P. G. Synthetic alkyl-phospholipid analogs: a new class of antitumor agents. In: J. F. Kuo (ed.), Phospholipids and Cellular Regulation, Vol. II, pp. 41-73. Boca Raton, FL: CRC Press, 1986.
2. Okamoto, S., Olson, A. C., and Vogler, W. R. Elimination of leukemic cells by the combined use of ether lipids in vitro. Cancer Res., 47: 2599-2603, 1987.
3. Andreesen, R. Ether lipids in the therapy of cancer. Prog. Biochem. Pharmacol., 22: 118-131, 1988.
4. Daniel, L. W. Ether lipids in experimental cancer chemotherapy. In: J. A. Hickman and R. T. Tritton (eds.), Cancer Chemotherapy, pp. 146-178. Oxford: Blackwell Scientific, 1993.
5. 3. Lipids, 22: 967-969, 1987.
6. Drings, P., Gunther, I., Gatzemeier, U., Ulbrich, F., Khanavkar, B., Schreml, W., Lorenz, J., Brugger, W., Schick, H. D., Pawel, J. V., and Nordstrom, R. Final evaluation of a phase II study on the effects of edelfosine (an ether lipid) in advanced non-small-cell bronchogenic carcinoma. Onkologie, 15: 375-382, 1992.
7. Vogler, W. R., Olson, A. C., Berdel, W. E., Okamoto, S., and Glasser, L. Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results. In: Bone Marrow Purging and Processing, pp. 1-20. New York: Alan R. Liss, Inc., 1990.
8. Dietzfelbinger, H. F., Kuhn, D., Zaffcrani, M., Hanauske, A. R., Rastetter, J. W., and Berdel, W. E. Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation. Cancer Res., 53: 3747-3751, 1993.
9. Andreesen, R., and Munder, P. G. Cell-destructive activity in serum of a tumor patient after infusion of alkyl lysophospholipid. J. Natl. Cancer Inst., 70: 623-627, 1983.
10. Lohmeyer, M., and Bittman, R. Antitumor ether lipids and alkylphosphocholines. Drugs of the Future, 19: 1021-1037, 1994.
11. Bittman, R. Chemical preparation of glycerolipids: a review of recent syntheses. In: G. Cevc (ed.), Phospholipids Handbook, pp., 141-232. New York: Marcel Dekker, Inc., 1993.
12. Modolell, M., Andreesen, R., Pahlke, W., Brugger, U., and Munder, P. G. Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res., 39: 4681-4686, 1979.
13. 3 acts as an activator of protein kinase C in HL-60 cells. FEBS Lett., 290: 231-234, 1991.
14. Andreesen, R., Osterholz, J., Luckenbach, G. A., Costabel, U., Schulz, A., Speth, V., Munder, P. G., and Lohr, G. W. Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. J. Natl. Cancer Inst., 72: 53-59, 1984.
15. Talmadge, J. E., Schneider, M., Lenz, B., Phillips, H., and Long, C. Immunomodulatory and therapeutic properties of alkyl lysophospholipids in mice. Lipids, 22: 871-877, 1987.
16. Berdel, W. E., and Munder, P. G. Antineoplastic actions of ether lipids related to platelet-activating factor. In: F. Snyder (ed.), Platelet-activating Factor and Related Lipid Mediators, pp. 449-468. New York: Plenum Publishing Corp., 1987.
17. Weinstein, N. J. Liposomes in the diagnosis and treatment of cancer. In: Marc. J. Ostro (ed.), Liposomes from Biophysics to Therapeutics, pp. 277-388. New York: Marcel Dekker, Inc., 1987.
18. Szoka, F. C., and Tang, M. Amphotericin B formulated in liposomes and lipid based systems: a review. J. Liposome Res., 3: 363-375, 1993.
19. Gabizon, A. A. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv. Drug Delivery Rev., 16: 285-294, 1995.
20. Cowens, J. W., Creaven, P. J., Greco, W. R., Brenner, D. E., Tung, Y., Ostro, M., Pilkiewicz, F., Ginsberg, R., and Petrelli, N. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res., 53: 2796-2802, 1993.
21. Layton, D., Luckenbach, G. A., Andreesen, R., and Munder, P. G. The interaction of liposomes with cells: the relation of cell specific toxicity to lipid composition. Eur. J. Cancer, 16: 1529-1538, 1980.
22. Mayhew, E., Ahmad, I., Bhatia, S., Dause, R., Filep, J., Janoff, A. S., Kaisheva, E., Perkins, W., Zha, Y., and Franklin, J. C. Stability of association of 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine with liposomes is composition dependent. Biochim. Biophys. Acta, in press, 1997.
23. Ahmad, I., Filep, J. J., Franklin, C., Janoff, A. S., Maurio, F., Prior, L., Zha, Y., and Mayhew, E. Effect of ether-lipid liposomes against mouse tumors and human tumor xenografts. Proc. Am. Assoc. Cancer Res., 37: 388, 1996.
24. Perkins, W. R., Dause, R. B., Li, X., Franklin, J. C., Cabral-Lilly, D. J., Zha, Y., Dank, E. H., Mayhew, E., and Janoff, A. S. Combination of antitumor ether lipid with lipids of complementary molecular shape reduces its transfer to red cells. Biochim. Biophys. Acta, in press, 1997.
25. Szoka, F. C., and Papahadjopoulos, D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu. Rev. Biophys. Bioeng., 9: 467-508, 1980.
26. Gruner, S. M., Lenk, R. P., Janoff, A. S., and Ostro, M. J. Novel multilayered lipid vesicles: comparison of physical characteristics of multilamellar liposomes and stable plurilamellar vesicles. Biochemistry, 24: 2833-2842, 1985.
27. Berdel, W. E., Bausert, W. R., Weltzien, H. U., Modolell, M. L., Widmann, K. H., and Munder, P. G. The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma. Eur. J. Cancer, 16: 1199-1204, 1980.
28. Ngwenya, B. Z., Fiavey, N. P., and Mogashoa, M. M. Activation of peritoneal macrophages by orally administered ether analogues of lysophospholipids. Proc. Soc. Exp. Biol. Med., 197: 91-97, 1991.
29. Noseda, A., Godwin, P. L., and Modest, E. J. Effects of antineoplastic ether lipids on model and biological membranes. Biochim. Biophysics. Acta, 945: 92-100, 1988.
30. Kotting, J., Marschner, N. W., Neumuller, W., Unger, C., and Eibl, H. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. Prog. Exp. Tumor Res., 34: 131-142, 1992.
31. Mayhew, E., and Papahadjopoulos, D. Therapeutic applications of liposomes. In: Marc J. Ostro (ed.), Liposomes, pp. 289-341. New York: Marcel Dekker, Inc., 1983.
32. Park, Y. S., Maruyama, K., and Huang, L. Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo. Biochim. Biophys. Acta, 1108: 257-260, 1992.
33. Luckenbach, G. A., and Layton, D. Liposomally activated macrophages: subsequent interaction with L1210 leukemic cells. Int. J. Cancer, 27: 837-839, 1981.
34. Reed, C. B., Tang, W., and Ziboh, V. A. Antineoplastic ether-linked phospholipid induces differentiation of acute myelogenous leukemic KG-1 cells into macrophage-like cells. Life Sci., 49: 1221-1227, 1991.
35. Huang, S. K., Mayhew, E., Gilani, S., Lasic, D. D., Martin, F. J., and Papahadjopoulos, D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res., 52: 6774-6781, 1992.
36. 3. Cancer Chemother. Pharmacol., 34: 175-178, 1994.